This was seen recently in January 2025, when GSK (LSE/NYSE: GSK) acquired IDRx, a Boston-based biotech specializing in precision therapies for gastrointestinal stromal tumors (GIST). Initially, GSK ...

GSK on Monday said that the European Medicines Agency has agreed to review a request to approve the British drugmaker's ...

GSK shares are trading cheaply and offering potential passive income. So is this FTSE 100 stock a no-brainer buy for my ...

Farther Finance Advisors LLC decreased its holdings in shares of GSK plc (NYSE:GSK – Free Report) by 27.4% during the fourth ...

Shares of GSK PLC GSK slipped 1.73% to £15.05 Wednesday, on what proved to be an all-around positive trading session for the ...

We recently published a list of the 7 Most Undervalued Biotech Stocks To Invest In. In this article, we are going to take a ...

Swiss drugmaker Roche has abandoned global diverse workforce targets and compatriot Novartis is ending its use of diverse ...

Pfizer (PFE) stock in focus as the company sells its entire 7.3% stake in Haleon (HLN) for $3.24B. Read more here.

Curevo has set its sights on competing with GSK’s shingles vaccine dominance by securing $110m and securing a former ...

In its effort to rival GSK’s shingles vaccine Shingrix, Curevo Vaccine has circled up $110 million and recruited two former ...

ViiV Healthcare, the global specialist HIV company majority owned by GSK, with Pfizer and Shionogi as shareholders, today announced positive findings from the company’s EMBRACE phase IIb study.

ViiV Healthcare's EMBRACE study shows VH109 with CAB LA effectively suppresses HIV. The company also reports promising early ...